SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Immix Biopharma Trial Results Selected for ASH 2026 Oral Presentation

Interim results from Immix Biopharma’s NXC-201 NEXICART-2 clinical trial were selected for an oral presentation at ASH 2026.

IMMX
SquawkNews Desk 1 updates Updated Nov 04, 2026, 02:22 PM UTC

Story updates

02:22:00 PM UTC
SquawkNews
Immix Biopharma to Present NXC-201 Trial Data From 45 Patients at ASH 2026 Immix Biopharma will

Related stories

Ronesans Gayrimenkul Q3 Revenue Rises to 4.8 Billion Lira Q3 revenue was 4.8 billion lira, compared with 4.0 billion lira a year earlier. M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC Ronesans Gayrimenkul Yatirim Reports Q3 Net Profit of 5.3 Billion Lira Net profit was 5.3 billion lira, compared with 11.6 billion lira a year earlier. M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC Google invertirá USD 15.000 millones en Malasia La inversión prevista contempla centros de datos, energía y agua. M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC General Motors shares hit record high, up 4% M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC SolarEdge Reports Q3 Revenue of $326.1 Million, Adjusted EPS of $0.29 Third-quarter revenue was $326.1 million, in line with the midpoint of prior guidance. Adjusted EPS was $0.29 versus FactSet consensus of $0.04. SolarEdge forecast fourth-quarter r M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC Kempower Reports Q3 Revenue Decline and Lowers 2026 Guidance Kempower reported a 10% revenue decline and negative operative EBIT in Q3 2026, citing weakening charging investment. It lowered full-year 2026 guidance, while reporting a €128 mil M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC